No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
KRMD240719C5000
- 0.02
- 0.000.00%
15min DelayClose Jul 17 15:55 ET
0.00High0.00Low
0.02Open0.02Pre Close0 Volume8 Open Interest5.00Strike Price0.00Turnover471.86%IV89.43%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type0.0562Delta0.1189Gamma132.50Leverage Ratio-0.0177Theta0.0000Rho7.44Eff Leverage0.0002Vega
Intraday
- 5D
- Daily
News
KORU Medical Systems to Report Second Quarter 2024 Financial Results on August 7, 2024
KORU Medical Systems (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume
Craig-Hallum Maintains KORU Medical Systems(KRMD.US) With Buy Rating
Craig-Hallum analyst Chase Knickerbocker maintains $KORU Medical Systems(KRMD.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 42.6% and a total average return of 2
Express News | KORU Medical Systems Receives Regulatory Clearance for Freedomedge® Infusion System in Japan
KORU Medical Systems Receives Regulatory Clearance for FreedomEdge Infusion System in Japan
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large
CCORF Maintains KORU Medical Systems(KRMD.US) With Buy Rating, Maintains Target Price $3
CCORF analyst Caitlin Cronin maintains $KORU Medical Systems(KRMD.US)$ with a buy rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 34.8% and a
Craig-Hallum Maintains KORU Medical Systems(KRMD.US) With Buy Rating, Raises Target Price to $150
Craig-Hallum analyst Chase Knickerbocker maintains $KORU Medical Systems(KRMD.US)$ with a buy rating, and adjusts the target price from $4 to $150.According to TipRanks data, the analyst has a success
Comments
$KORU Medical Systems(KRMD.US$ Reuters · 1 min ago KORU Medical Systems Receives Regulatory Clearance for Freedomedge® Infusion System in Japan
$KORU Medical Systems(KRMD.US$
KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic
KORU Medical Systems (NASDAQ: KRMD) announced a collaboration with a global pharmaceutical company to initiate a feasibility study for their Freedom Infusion System. This system, designed for subcutaneous administration, will be tested with an FDA and EMA approved oncology biologic drug currently administered manually by healthcare professionals. The Freedom System, ...
KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic
KORU Medical Systems (NASDAQ: KRMD) announced a collaboration with a global pharmaceutical company to initiate a feasibility study for their Freedom Infusion System. This system, designed for subcutaneous administration, will be tested with an FDA and EMA approved oncology biologic drug currently administered manually by healthcare professionals. The Freedom System, ...
2
$KORU Medical Systems(KRMD.US$
NEWS
KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth
First quarter 2024 net revenues of $8.2 million, an 11% increase YoY and record high quarterly revenues.
Core business (U.S. and International) experienced 14% growth YoY, driven by SCIg market growth, share gains, and geographic expansion.
Entered a Novel Therapies collaboration with an oncology drug therapy, bringing total collaborations to 16.
G...
NEWS
KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth
First quarter 2024 net revenues of $8.2 million, an 11% increase YoY and record high quarterly revenues.
Core business (U.S. and International) experienced 14% growth YoY, driven by SCIg market growth, share gains, and geographic expansion.
Entered a Novel Therapies collaboration with an oncology drug therapy, bringing total collaborations to 16.
G...
$KORU Medical Systems(KRMD.US$ KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth
2
...do you own all of these stocks you post or are you just posting stocks that you think will run up?
$KORU Medical Systems(KRMD.US$ how far can this baby crawl?
Read more